Key result
Intravenous nesiritide reduced pulmonary capillary wedge pressure at 3 hours more effectively than placebo (-5.8 vs -2 mm Hg, P<0.001) and nitroglycerin (-3.8 mm Hg, P=0.03) in decompensated CHF.
Why the study?
Does intravenous nesiritide improve hemodynamics and dyspnea compared to intravenous nitroglycerin or placebo in inpatients with acutely decompensated congestive heart failure?
Population
489 inpatients with dyspnea at rest from decompensated congestive heart failure, including 246 who received…
Comparison
Intravenous nesiritide added to standard… vs Intravenous nitroglycerin or placebo added to…
Design
RCT, Randomized, double-blind
Follow-up
24 hours
Loading...
Supports nesiritide for superior acute PCWP reduction in decompensated HF; extends RCT evidence beyond placebo to active vasodilator comparison.
RCT (n=489)
Double-blind
Randomized
Yes
Does intravenous nesiritide improve hemodynamics and dyspnea compared to intravenous nitroglycerin or placebo in inpatients with acutely decompensated congestive heart failure?
Absolute Event Rate: -5.8% vs -2%
p-value: p=<.001
Intravenous nesiritide provides greater reduction in pulmonary capillary wedge pressure compared to intravenous nitroglycerin or placebo in patients with acutely decompensated heart failure, though symptom improvement differences are modest.
A 2002 study conducted an RCT in Decompensated congestive heart failure (n=489). Intravenous nesiritide vs. Intravenous nitroglycerin or placebo was evaluated on Change in pulmonary capillary wedge pressure (PCWP) and patient self-evaluation of dyspnea at 3 hours (p=<.001). Intravenous nesiritide reduced pulmonary capillary wedge pressure at 3 hours more effectively than placebo (-5.8 vs -2 mm Hg, P<0.001) and nitroglycerin (-3.8 mm Hg, P=0.03) in decompensated CHF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: